Alyeska Investment Group’s Coherus Oncology CHRS Stock Holding History

Alyeska Investment Group’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.43M	Sell	1,733,234 -516,766	-23%	-$844K	0.01%	561
2026 Q1	$3.8M	Buy	+2,250,000	New	+$4M	0.01%	505
2018 Q4	–	Sell	-100,000	Closed	-$1.65M	–	377
2018 Q3	$1.65M	Sell	100,000 -298,717	-75%	-$5.3M	0.02%	316
2018 Q2	$5.58M	Sell	398,717 -57,860	-13%	-$828K	0.05%	266
2018 Q1	$5.04M	Sell	456,577 -28,004	-6%	-$306K	0.04%	287
2017 Q4	$4.26M	Sell	484,581 -75,000	-13%	-$803K	0.03%	273
2017 Q3	$7.47M	Sell	559,581 -26,446	-5%	-$350K	0.06%	267
2017 Q2	$8.41M	Buy	586,027 +136,027	+30%	+$2.62M	0.07%	252
2017 Q1	$9.52M	Buy	+450,000	New	+$11.1M	0.08%	261
2015 Q1	–	Sell	-34,183	Closed	-$558K	–	502
2014 Q4	$558K	Buy	+34,183	New	+$482K	0.01%	434

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Alyeska Investment Group's CHRS Position: Q2 2026 in Review

Alyeska Investment Group reduced its Coherus Oncology (CHRS) stake by 23% in Q2 2026, selling an estimated $844K and leaving 1,733,234 shares worth $2.43M. The position accounts for 0.01% of the portfolio, ranked #561.

Alyeska Investment Group first reported a position in CHRS in Q4 2014 and has held it in 10 quarters since. The position peaked at $9.52M in Q1 2017. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

Alyeska Investment Group held 1,733,234 shares of Coherus Oncology worth $2.43M as of Q2 2026.
Alyeska Investment Group sold 516,766 Coherus Oncology shares in Q2 2026, an estimated $844K.
Coherus Oncology made up 0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #561 holding.
Alyeska Investment Group first reported a position in Coherus Oncology in Q4 2014 and has held it in 10 quarters since.
Alyeska Investment Group's Coherus Oncology position peaked at $9.52M in Q1 2017.
147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.